Zenas BioPharma的动态

6,588 位关注者

1 个月

We are thrilled to share the news of our IPO and to be Nasdaq-listed as ZBIO! This financing allows Zenas Bio to continue to advance our mission to become a global leader in the development and commercialization of immunology-based therapies so that patients with autoimmune diseases can reimagine life. Thank you to everyone who has supported us! ? #IPO #Nasdaqlisted #ZenasBio #immunology #autoimmunediseases

36 条评论

Andrea Rabney

Founder and CEO at Argot Partners

1 个月

Congratulations! So happy for the Zenas team.

3 次回应

Kathleen Arntsen

President & CEO of Lupus and Allied Diseases Association, Inc., National Autoimmune Patient Advocate and Advocacy Community Leader

3 周

This is wonderful news and inspiring to all living with autoimmune disease. Lupus and Allied Diseases Association, Inc.

1 次回应

Steven Gersten

Senior Biotech/Biopharmaceutical/Medical Device Legal and Compliance Executive -- Board Member --- Advisor

1 个月

Congratulations to the Zenas team for this significant achievement. ?Wishing you the best as you proceed as a public company. ?

Florent Cameron

PharmD_Associate Director, Medical Affairs Europe

1 个月

Congratulations Zenas! What an amazing milestone for our company! So happy and proud to be part this fantastic team.

1 次回应

Gopi Krishna Nandiraju

Director, Client Partner - Consumer & Retail

1 个月

Congratulations and keep growing ??

Keith Mikule

Business Development & Alliance Management Leader

1 个月

Congratulations to the whole team, this is great news!

Jennifer Short

Research Assistant, Business Development at Slone Partners

1 个月

Congratulations! Looking forward to continuing to follow your progress!

Erik Schaffner

1 个月

Congrats to the ZENAS Team

Chinese Antibody Society

1 个月

Congratulations!

Konstantina Katcheves

Senior Vice President, Innovative Medicines Global Business Development and Acquisitions at Teva Pharmaceuticals

4 周

Congratulations to the Zenas team!

1 次回应

查看更多评论

要查看或添加评论，请登录

最相关的动态

Cambridge Bioscience

7,778 位关注者
4 个月
举报此动态
?? Enhance your complement research with Hycult Biotech ?? Hycult Biotech is your go-to partner for complement research tools. With expertise in assays, antibodies, and proteins, you can rely on their high-quality products for reliable results. Check out the PDF below to explore: ?? Complement function assays ?? ELISA kits ?? Specialised antibodies ...and more! #Antibodies #Bioscience #Immunology #Assays
赞评论
要查看或添加评论，请登录
Ira S. Pastor

Host, Progress, Potential, And Possibilities
8 个月
举报此动态
Advancing The Development Of Targeted mRNA And Nanomedicine Therapeutics - Dr. #DrewWeissman, MD, PhD - 2023 #NobelPrize Laureate in Medicine; Director, #Penn Institute for RNA #Innovation #ProgressPotentialAndPossibilities #Penn #NobelPrize #DrewWeissman #mRNA #Vaccines #Immunology #CarTCells #CancerTherapeutics #Nanomedicine #LipidNanoparticles #GeneEditing #GeneTherapy #CellTherapy #StemCells
赞评论
要查看或添加评论，请登录
Kate Lee

Working at Alpha Lifetech Inc.
5 个月
举报此动态
Humanized antibodies like daclizumab, which targets the IL-2 receptor on activated T cells, have been used in the treatment of multiple sclerosis, reducing the frequency of relapses. https://lnkd.in/gShNmC7J #Daclizumab #IL2Receptor #ActivatedTCells #MultipleSclerosis #AntibodyTreatment #HumanizedAntibodies #RelapseReduction #MSResearch #Immunotherapy #IL2 #AlphaLifeTech #AntibodyHumanization #Biotechnology #Immunology #TherapeuticAntibodies #HealthcareInnovation
赞评论
要查看或添加评论，请登录
Alpha Lifetech Inc.

36 位关注者
5 个月
举报此动态
Humanized antibodies like daclizumab, which targets the IL-2 receptor on activated T cells, have been used in the treatment of multiple sclerosis, reducing the frequency of relapses. https://lnkd.in/g-MJ2Rxb #Daclizumab #IL2Receptor #ActivatedTCells #MultipleSclerosis #AntibodyTreatment #HumanizedAntibodies #RelapseReduction #MSResearch #Immunotherapy #IL2 #AlphaLifeTech #AntibodyHumanization #Biotechnology #Immunology #TherapeuticAntibodies #HealthcareInnovation
赞评论
要查看或添加评论，请登录
Phialogics - The immune tolerance company

651 位关注者
6 个月
举报此动态
Good opportunity for Andreas Ernst to present the last developments of Phialogics - The immune tolerance company during the BioLabs Investor Day in Paris few days ago. Thanks for the event organization and the networking sessions where we met leading investors and pharmas. Looking forward to more updates in the coming weeks ! #biotech #immunology
赞评论
要查看或添加评论，请登录
Altasciences

32,887 位关注者
9 个月已编辑
举报此动态
In this edition of The Altascientist, learn about the different purposes and challenges of validating immunogenicity assays to strategically develop a safe and quick approach to support nonclinical and clinical studies. #DrugDevelopment #Immunology #Laboratory
赞评论
要查看或添加评论，请登录
Natalie Osborne

Senior Scientist and Sustainability Champion at Nexus Bioquest.
6 个月
举报此动态
Here we describe our in vitro NETosis and phagocytosis/trogocytosis assays, complementing our existing ROS and migration assays. Get in touch to learn more. #NexusBioQuest #NETosis #Neutrophils #Phagocytosis

Nexus BioQuest

1,160 位关注者
7 个月

For those focusing on therapeutic interventions targeting Neutrophils, Nexus BioQuest provides a range of in vitro human neutrophil assays. Here we describe NETosis and phagocytosis/trogocytosis assays, complementing our existing ROS and migration assays. If you would like more information please email [email protected] or visit our website www.nexusbioquest.com to schedule a call with one of our Scientists.#drugdiscovery #immunotherapy #immunology
赞评论
要查看或添加评论，请登录
Berencia Fore

Helping researchers design their flow cytometry panels!
6 个月
举报此动态
Let’s talk flow - A flow cytometry monthly meetup We are excited to invite you to our 1st live session of “Let’s Talk Flow”. A virtual, monthly meetup to learn more about flow cytometry best practices. This month, we'll delve into the most effective techniques and realistic considerations for performing antibody titrations. Did you know that titrating your antibodies is a key step in the flow cytometry workflow to minimize non-specific binding? Learn more on Wednesday, April 24, 2024! We are offering two sessions for your convenience: Register Today! 1st - 10AM CET/1:30PM IST/6PM AEST: https://lnkd.in/gWpEeknc 2nd – 10AM PST/1PM EST/2PM BRT:? https://lnkd.in/g_9u_nqp We look forward to seeing you there! Until then, here are 3 important outcomes of titrating your antibodies: Maximize the separation between positive and negative populations. Minimize non-specific binding. Establish the highest labeling efficiency of your antibody. #flowcytometry #paneldesign #flow #immunology
赞评论
要查看或添加评论，请登录
Patricia Haus

Supervisor Technical Support Thermo Fisher Scientific
6 个月
举报此动态
Let’s talk flow - A flow cytometry monthly meetup We are excited to invite you to our 1st live session of “Let’s Talk Flow”. A virtual, monthly meetup to learn more about flow cytometry best practices. This month, we'll delve into the most effective techniques and realistic considerations for performing antibody titrations. Did you know that titrating your antibodies is a key step in the flow cytometry workflow to minimize non-specific binding? Learn more on Wednesday, April 24, 2024! We are offering two sessions for your convenience: Register Today! 1st - 10AM CET/1:30PM IST/6PM AEST: https://lnkd.in/gWpEeknc 2nd – 10AM PST/1PM EST/2PM BRT:? https://lnkd.in/g_9u_nqp We look forward to seeing you there! Until then, here are 3 important outcomes of titrating your antibodies: Maximize the separation between positive and negative populations. Minimize non-specific binding. Establish the highest labeling efficiency of your antibody. #flowcytometry #paneldesign #flow #immunology
赞评论
要查看或添加评论，请登录
Carl Gunderson

Manager, Technical Support at Thermo Fisher Scientific
6 个月
举报此动态
Let’s talk flow - A flow cytometry monthly meetup We are excited to invite you to our 1st live session of “Let’s Talk Flow”. A virtual, monthly meetup to learn more about flow cytometry best practices. This month, we'll delve into the most effective techniques and realistic considerations for performing antibody titrations. Did you know that titrating your antibodies is a key step in the flow cytometry workflow to minimize non-specific binding? Learn more on Wednesday, April 24, 2024! We are offering two sessions for your convenience: Register Today! 1st - 10AM CET/1:30PM IST/6PM AEST: https://lnkd.in/gWpEeknc 2nd – 10AM PST/1PM EST/2PM BRT:? https://lnkd.in/g_9u_nqp We look forward to seeing you there! Until then, here are 3 important outcomes of titrating your antibodies: Maximize the separation between positive and negative populations. Minimize non-specific binding. Establish the highest labeling efficiency of your antibody. #flowcytometry #paneldesign #flow #immunology
赞评论
要查看或添加评论，请登录

6,588 位关注者

查看档案关注

登录查看更多内容